40 Result(s)
within
Jennifer R. Grandis
-
Article
Open AccessRare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets
In vitro biopanning platforms using synthetic phage display antibody libraries have enabled the identification of antibodies against antigens that were once thought to be beyond the scope of immunization. Appl...
-
Article
Author Correction: Head and neck squamous cell carcinoma
-
Article
Open AccessCaspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction
The cysteine protease, caspase-8, undergoes dimerization, processing, and activation following stimulation of cells with death ligands such as TRAIL, and mediates TRAIL induction of the extrinsic apoptosis pat...
-
Article
Open AccessDisruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
Immune checkpoint blockade (ICB) therapy has revolutionized head and neck squamous cell carcinoma (HNSCC) treatment, but <20% of patients achieve durable responses. Persistent activation of the PI3K/AKT/mTOR s...
-
Chapter
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma: Opportunities for Detection and Monitoring Via Analysis of Circulating Tumor DNA
The mutational landscape of head and neck squamous cell carcinoma (HNSCC) has been elucidated in the past decade. Even though HNSCC tumors are relatively accessible for sampling, the opportunity to determine t...
-
Article
Head and neck squamous cell carcinoma
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx can...
-
Article
Open AccessHER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma
BYL719 is a PI3K inhibitor that has demonstrated efficacy in the treatment of head and neck squamous cell carcinoma. BYL719 exerts its therapeutic effect by suppressing AKT and other proliferative signaling me...
-
Article
Open AccessAPOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma
Recent studies have revealed the mutational signatures underlying the somatic evolution of cancer, and the prevalences of associated somatic genetic variants. Here we estimate the intensity of positive selecti...
-
Article
Open AccessAnalysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer death in the US. The protein kinase D (PKD) family has emerged as a promising target for cancer therapy with PKD1 being most i...
-
Article
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
The IL-6/JAK/STAT3 signalling pathway is aberrantly hyperactivated in patients with chronic inflammatory conditions and in those with haematopoietic malignanci...
-
Protocol
High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines
In the canonical STAT3 signaling pathway, IL-6 receptor engagement leads to the recruitment of latent STAT3 to the activated IL-6 complex and the associated Janus kinase (JAK) phosphorylates STAT3 at Y705. pST...
-
Chapter
Jak/STAT Signaling in Head and Neck Cancer
The Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway conveys cytokine receptor and receptor tyrosine kinase activation signals to the nucleus, leading to alteration of gene expr...
-
Article
EGFR-targeted therapies in the post-genomic era
Over 90% of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targetin...
-
Article
Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines
Studies indicate that elevated interleukin-6 (IL-6) levels engage IL6Rα-gp130 receptor complexes to activate signal transducer and activator of transcription 3 (STAT3) that is hyperactivated in many cancers in...
-
Article
A watershed year for improvements in treatment?
In the past year, clinical trials have provided important information on strategies to decrease treatment-associated toxicities in patients with head and neck cancer. In addition, the FDA approved the first im...
-
Article
Open AccessExome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understa...
-
Article
Spot the difference
A molecular analysis of human oesophageal cancers reveals abnormalities that might be targetable by existing drugs, and indicates that the current stratification of these tumours into subtypes is incomplete. See ...
-
Article
Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation
The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) promotes gene transcription involved in cancer, and its activation by IL-6 is found in head and neck squamous cell ...
-
Article
Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer
Paul Brennan and colleagues perform genome-wide association analysis for oral cavity and pharyngeal cancer in trans-ancestry populations. They find seven new loci across different cancer subtypes, including a ...
-
Chapter
STAT Proteins in Cancer
The seven members of the signal transducer and activator of transcription (STAT) family of proteins are transcription factors that are activated in response to, and mediate signaling downstream of, growth fact...
